A5071944551- Pituitary Gland Disorders and Treatments
- Histone Deacetylase Inhibitors Research
- Cancer Cells and Metastasis
- Growth Hormone and Insulin-like Growth Factors
- Oral and Maxillofacial Pathology
- Meningioma and schwannoma management
- Advanced Materials Characterization Techniques
- Neuroendocrine Tumor Research Advances
- Explainable Artificial Intelligence (XAI)
- Cancer, Hypoxia, and Metabolism
University of California, San Francisco
2022-2024
INTRODUCTION: The cellular origins of pituitary neuroendocrine tumors (PitNETs) are uncertain, positing that PitNETs may originate from differentiated cells or adult stem cells. Understanding these is essential for developing targeted therapies aimed at tumor-initiating cells, thereby enhancing treatment efficacy. METHODS: We conducted single-nucleus sequencing on approximately half a million creating the largest database to date. This included samples two non-tumor postmortem pituitaries...
Abstract Glioblastoma (GBM), a challenging brain tumor, necessitates the development of new therapies due to poor patient prognoses, with median survival 14-16 months. Standard care, as established almost 20 years ago, remains be surgical resection followed by chemotherapy and radiation till date there is no defined standard care for recurrent GBM, highlighting urgent need novel therapies. Recent studies have implicated tumor microenvironment in these prognoses. While cancer associated...
OBJECTIVE There is persistent debate in the literature surrounding true predictors of biochemical remission after resection somatotroph adenoma. A multimodal analysis a large number patients needed to better understand which may be at higher or lower risk for failure surgery. METHODS retrospective review was performed on undergoing adenoma resection. Biochemical defined as age- and sex-adjusted normalization serum insulin growth factor-1 (IGF-1) levels least 6 months Patient case...